Cohance Lifesciences Limited – 8/12/2025. Country: India. Record Type: 483
Similar Posts
Ongoing | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.Medi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/06/2025
Short Title (70 char) Medi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025
FEI Number 3009925820
Firm Name Medi-Fare Drug Pharmaceutical Compounding LLC
Record Type 483Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
FOR IMMEDIATE RELEASE – Nov. 6,2025 – LAKE ZURICH, Ill.— Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is voluntarily recalling three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection, USP, 20 mgMy Dog Has Cancer: What Do I Need to Know?
Just as FDA reviews drugs for humans for safety and effectiveness before they can go on the market, the agency does the same for treatments for animals. Learn how FDA brings new oncology treatments to market and questions to ask your vet about your dog’s cancer diagnosis.Nat’s Nuts Issues Allergy Alert on Potential Undeclared Cashews in Nat’s Nuts Brand Cinnamon Whiskey Pecans
Nat’s Nuts of Rochester, NY is recalling 600 bags of Cinnamon Whiskey Pecans, because they may contain undeclared cashews. People who have an allergy or severe sensitivity to cashews run the risk of serious or life-threatening allergic reaction if they consume these products.Patient Listening Session Summaries
Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.